Integrated Analysis of Drug-Induced Gene Expression Profiles Predicts Novel hERG Inhibitors

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Babcock, Joseph J ^a   Du, Fang ^a   Xu, Kaiping ^a   Wheelan, Sarah J ^a   Li, Min ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPERASTINE; FENDILINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG INHIBITOR; PROFENAMINE; SULCONAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CLUSTER ANALYSIS; CONNECTIVITY MAP; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; DRUG INDICATION; DRUG STRUCTURE; DRUG TARGETING; ELECTROPHYSIOLOGY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HERGCENTRAL DATABASE; HUMAN; HUMAN CELL; INFORMATION PROCESSING; LONG QT SYNDROME; NONHUMAN; PROTEIN TARGETING;

CLUSTER ANALYSIS; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACEUTICAL PREPARATIONS; POTASSIUM CHANNEL BLOCKERS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC;

EID: 84880735292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069513     Document Type: Article

References (66)

1. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181. doi:10.1038/nature08506. PubMed: 19881490.
2. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science 321: 263-266. doi:10.1126/science.1158140. PubMed: 18621671.
3. Fliri AF, Loging WT, Thadeio PF, Volkmann RA, (2005) Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 1: 389-397. doi:10.1038/nchembio747. PubMed: 16370374.
4. Xie L, Kinnings SL, Bourne PE, (2012) Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 52: 361-379. doi:10.1146/annurev-pharmtox-010611-134630. PubMed: 22017683.
5. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, et al. (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3: 96ra76.
6. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621-14626. doi:10.1073/pnas.1000138107. PubMed: 20679242.
7. Tropsha A, Golbraikh A, (2007) Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des 13: 3494-3504. doi:10.2174/138161207782794257. PubMed: 18220786.
8. Nigsch F, Lounkine E, McCarren P, Cornett B, Glick M, et al. (2011) Computational methods for early predictive safety assessment from biological and chemical data. Expert Opin Drug Metab Toxicol 7: 1497-1511. doi:10.1517/17425255.2011.632632. PubMed: 22050465.
9. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935. doi:10.1126/science.1132939. PubMed: 17008526.
10. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3: 96ra77.
11. Toyoshiba H, Sawada H, Naeshiro I, Horinouchi A, (2009) Similar compounds searching system by using the gene expression microarray database. Toxicol Lett 186: 52-57. doi:10.1016/j.toxlet.2008.08.009. PubMed: 18801419.
12. Lee S, Lee K, Song M, Lee D, (2011) Building the process-drug-side effect network to discover the relationship between biological Processes and side effects. BMC Bioinformatics 12: S2. doi:10.1186/1471-2105-12-S1-S2.
13. Sanguinetti MC, Tristani-Firouzi M, (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469. doi:10.1038/nature04710. PubMed: 16554806.
14. Suessbrich H, Waldegger S, Lang F, Busch AE, (1996) Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 385: 77-80. doi:10.1016/0014-5793(96)00355-9. PubMed: 8641472.
15. Mohammad S, Zhou Z, Gong Q, January CT, (1997) Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273: H2534-H2538. PubMed: 9374794.
16. Roy M, Dumaine R, Brown AM, (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94: 817-823. doi:10.1161/01.CIR.94.4.817. PubMed: 8772706.
17. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, et al. (2011) Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471: 225-229. doi:10.1038/nature09747. PubMed: 21240260.
18. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, et al. (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363: 1397-1409. doi:10.1056/NEJMoa0908679. PubMed: 20660394.
19. Zou B, Yu H, Babcock JJ, Chanda P, Bader JS, et al. (2010) Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-a-go-go related gene potassium channels. Assay Drug Dev Technol 8: 743-754. doi:10.1089/adt.2010.0339. PubMed: 21158688.
20. Potet F, Lorinc AN, Chaigne S, Hopkins CR, Venkataraman R, et al. (2012) Identification and characterization of a compound that protects cardiac tissue from human Ether-a-go-go-related gene (hERG)-related drug-induced arrhythmias. J Biol Chem 287: 39613-39625. doi:10.1074/jbc.M112.380162. PubMed: 23033485.
21. Petersen CI, McFarland TR, Stepanovic SZ, Yang P, Reiner DJ, et al. (2004) In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci U S A 101: 11773-11778. doi:10.1073/pnas.0306005101. PubMed: 15280551.
22. Rubinstein AL, (2006) Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2: 231-240. doi:10.1517/17425255.2.2.231. PubMed: 16866609.
23. Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, et al. (2002) Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem 277: 18528-18534. doi:10.1074/jbc.M200592200. PubMed: 11893742.
24. Roy J, Vantol B, Cowley EA, Blay J, Linsdell P, (2008) Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7. Oncol Rep 19: 1511-1516. PubMed: 18497958.
25. Berger SI, Ma. ayan A, Iyengar R (2010) Systems pharmacology of arrhythmias. Sci Signal 3: 30.
26. Du F, Yu H, Zou B, Babcock J, Long S, et al. (2011) hERGCentral: a large database to store, retrieve, and analyze compound-human Ether-a-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay Drug Dev Technol 9: 580-588. doi:10.1089/adt.2011.0425. PubMed: 22149888.
27. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, et al. (2010) Drug-Induced Regulation of Target Expression. PLOS Comput Biol 6: e1000925.
28. Frey BJ, Dueck D, (2007) Clustering by passing messages between data points. Science 315: 972-976. doi:10.1126/science.1136800. PubMed: 17218491.
29. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45. doi:10.1016/S0008-6363(02)00846-5. PubMed: 12667944.
30. Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, et al. (2009) A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 60: 152-158. doi:10.1016/j.vascn.2009.05.011. PubMed: 19616110.
31. Kang J, Chen XL, Wang L, Rampe D, (2001) Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 299: 290-296. PubMed: 11561091.
32. Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, et al. (2005) Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol 144: 840-848. doi:10.1038/sj.bjp.0706095. PubMed: 15778703.
33. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, et al. (2011) Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 91: 53-61. doi:10.1093/cvr/cvr044. PubMed: 21300721.
34. Davies MR, Mistry HB, Hussein L, Pollard CE, Valentin JP, et al. (2012) An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. Am J Physiol Heart Circ Physiol 302: H1466-H1480. doi:10.1152/ajpheart.00808.2011. PubMed: 22198175.
35. Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, et al. (2009) A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med 15: 509-518. doi:10.1038/nm.1962. PubMed: 19412172.
36. Hofmann G, Bernabei PA, Crociani O, Cherubini A, Guasti L, et al. (2001) HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG. J Biol Chem 29. 1: 276: 4923-4931.
37. Shah RR, (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54: 188-202. doi:10.1046/j.1365-2125.2002.01627.x. PubMed: 12207642.
38. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-D1107. doi:10.1093/nar/gkr777. PubMed: 21948594.
39. Yuill KH, Borg JJ, Ridley JM, Milnes JT, Witchel HJ, et al. (2004) Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation. Biochem Biophys Res Commun 318: 556-561. doi:10.1016/j.bbrc.2004.04.063. PubMed: 15120636.
40. Zhou ZF, Gong QM, Ye B, Fan Z, Makielski JC, et al. (1998) Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74: 230-241. doi:10.1016/S0006-3495(98)77782-3. PubMed: 9449325.
41. Yu SP, Kerchner GA, (1998) Endogenous voltage-gated potassium channels in human embryonic kidney (HEK293) cells. J Neurosci Res 52: 612-617. doi:10.1002/(SICI)1097-4547(19980601)52:5. PubMed: 9632317.
42. Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T, (2005) Characterization of a hERG screen using the IonWorks HT: Comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol 3: 47-57. doi:10.1089/adt.2005.3.47. PubMed: 15798395.
43. Bridal TR, Margulis M, Wang X, Donio M, Sorota S, (2010) Comparison of human Ether-a-go-go related gene screening assays based on IonWorks Quattro and thallium flux. Assay Drug Dev Technol 8: 755-765. doi:10.1089/adt.2010.0267. PubMed: 20658944.
44. Kaczmarek LK, (2006) Non-conducting functions of voltage-gated ion channels. Nat Rev Neurosci 7: 761-771. doi:10.1038/nrn1988. PubMed: 16988652.
45. Gomez-Ospina N, Tsuruta F, Barreto-Chang O, Hu L, Dolmetsch R, (2006) The C terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor. Cell 127: 591-606. doi:10.1016/j.cell.2006.10.017. PubMed: 17081980.
46. Hegle AP, Marble DD, Wilson GF, (2006) A voltage-driven switch for ion-independent signaling by ether-a-go-go K+ channels. Proc Natl Acad Sci U S A 103: 2886-2891. doi:10.1073/pnas.0505909103. PubMed: 16477030.
47. Broccatelli F, Mannhold R, Moriconi A, Giuli S, Carosati E, (2012) QSAR Modeling and Data Mining Link Torsades de Pointes Risk to the Interplay of Extent of Metabolism, Active Transport, and hERG Liability. Mol Pharm 9: 2290-2301.
48. Huang X, Dubuc AM, Hashizume R, Berg J, He Y, et al. (2012) Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev 26: 1780-1796. doi:10.1101/gad.193789.112. PubMed: 22855790.
49. Nueda MJ, Sebastian P, Tarazona S, Garcia-Garcia F, Dopazo J, et al. (2009) Functional assessment of time course microarray data. BMC Bioinformatics 10 (Suppl 6):: S9. doi:10.1186/1471-2105-10-S1-S9.
50. Tan Y, Shi L, Hussain SM, Xu J, Tong W, et al. (2006) Integrating time-course microarray gene expression profiles with cytotoxicity for identification of biomarkers in primary rat hepatocytes exposed to cadmium. Bioinformatics 22: 77-87. doi:10.1093/bioinformatics/bti737. PubMed: 16249259.
51. Takashima K, Mizukawa Y, Morishita K, Okuyama M, Kasahara T, et al. (2006) Effect of the difference in vehicles on gene expression in the rat liver--analysis of the control data in the Toxicogenomics Project Database. Life Sci 78: 2787-2796. doi:10.1016/j.lfs.2005.11.010. PubMed: 16360708.
52. Doddareddy MR, Klaasse EC, Shagufta, Ijzerman AP, Bender A, (2010) Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases. Chemmedchem 5: 716-729. doi:10.1002/cmdc.201000024. PubMed: 20349498.
53. Li Q, Jorgensen FS, Oprea T, Brunak S, Taboureau O, (2008) hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol Pharm 5: 117-127. doi:10.1021/mp700124e. PubMed: 18197627.
54. Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, et al. (2010) Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol 381: 385-400. doi:10.1007/s00210-010-0496-7. PubMed: 20229012.
55. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, et al. (2007) VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110: 1238-1250. doi:10.1182/blood-2006-02-003772. PubMed: 17420287.
56. Zhang H, Zou B, Yu H, Moretti A, Wang X, et al. (2012) Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A 109: 11866-11871. doi:10.1073/pnas.1205266109. PubMed: 22745159.
57. Yang KC, Ku YC, Lovett M, Nerbonne JM, (2012) Combined deep microRNA and mRNA sequencing identifies protective transcriptomal signature of enhanced PI3Kalpha signaling in cardiac hypertrophy. J Mol Cell Cardiol 53: 101-112. doi:10.1016/j.yjmcc.2012.04.012. PubMed: 22580345.
58. Song HK, Hong SE, Kim T, Kim do H, (2012) Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. PLOS ONE 7: e35552. doi:10.1371/journal.pone.0035552. PubMed: 22523601.
59. Bagnall RD, Tsoutsman T, Shephard RE, Ritchie W, Semsarian C, (2012) Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLOS ONE 7: e44744. doi:10.1371/journal.pone.0044744. PubMed: 23024758.
60. Hochberg Y, Benjamini Y, (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818. doi:10.1002/sim.4780090710. PubMed: 2218183.
61. Li H, Zhou H, Wang D, Qiu J, Zhou Y, et al. (2012) Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery. Proc Natl Acad Sci U S A 109: 4609-4614. doi:10.1073/pnas.1200305109. PubMed: 22396588.
62. Bengtsson H, Simpson K, Bullard J, Hansen K, (2008) aroma.affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory.
63. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F, (2004) A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99: 909-917. doi:10.1198/016214504000000683.
64. R Development Core Team (2012) R: A Language and Environment for Statistical Computing.
65. Ma C, Chen H-IH, Huang Y, Chen Y, (2010) Constructing a compound mode-of-action network for personalized drug effectiveness prediction. Proceedings of the First ACM International Conference on Bioinformatics and Computational Biology. Niagara Falls, New York: ACM. 520-528.
66. Alexa A, Rahnenfuhrer J, (2010) topGO: topGO: Enrichment analysis for Gene Ontology.